DARTMOUTH-HITCHCOCK MEDICAL CENTER

FDA Approves Journavx, a Novel Non-Opioid Painkiller, Offering New Hope for Acute Pain Management

5 months ago

• The FDA has approved Journavx (suzetrigine), a first-in-class non-opioid analgesic, for treating moderate to severe acute pain in adults, offering a safer alternative to opioids. • Journavx works by selectively blocking pain signals in the peripheral nervous system, reducing pain without the addictive potential and severe side effects associated with opioids. • Clinical trials demonstrated Journavx's effectiveness in reducing pain after surgeries, with a safety profile comparable to placebo, though it didn't outperform opioid-acetaminophen combinations. • Priced at $15.50 per pill, Journavx faces challenges in accessibility due to its higher cost compared to generic opioids, but it represents a significant step in combating the opioid crisis.

AI Revolutionizes Cancer Detection: Breakthroughs in Liquid Biopsies, Imaging, and Pathology

5 years ago

• Advanced machine learning algorithms enable liquid biopsies for early lung cancer detection, potentially increasing annual lives saved from 600 to 12,000 in the United States through blood-based screening. • AI-powered imaging systems match radiologists' accuracy in breast cancer detection, demonstrating potential to reduce second reader workload by 88% in UK screening processes. • Deep neural networks in pathology achieve expert-level accuracy in tumor pattern classification, processing slides in under one minute while maintaining diagnostic quality comparable to practicing pathologists.